Pyrazoles, matrixscientific.com, Drugs acting on the gastrointestinal system and metabolism, Opioids, Five-membered rings, Psychoactive drugs, Antiobesity drugs, Opioid antagonists, Anxiogenics, Pharmaceuticals, Drugs acting on the nervous system

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) was an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was the first drug approved in that class.